Filtered By:
Therapy: Stem Cell Therapy
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 790 results found since Jan 2013.
Mechanisms of Potential Therapeutic Utilization of Mesenchymal Stem Cells in COVID-19 Treatment
Cell Transplant. 2023 Jan-Dec;32:9636897231184611. doi: 10.1177/09636897231184611.ABSTRACTThe 2019 novel coronavirus disease (COVID-19) has lasted for over 3 years and has seriously affected the regular life trajectory of human beings. The severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) has caused non-negligible harm to people's respiratory systems and multiple organs. Although the pathogenesis of COVID-19 has been fully elucidated, there is still a lack of effective and specific treatment for COVID-19. Mesenchymal stem cells (MSCs) or MSC-derived extracellular vesicles (MSC-EVs) by far have become the mos...
Source: Cell Transplantation - July 3, 2023 Category: Cytology Authors: Yuyin Fang Peizhen Lao Longqian Tang Jingyi Chen Yuxi Chen Lei Sun Wenwen Tan Xingliang Fan Source Type: research
Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial
CONCLUSION: MSCs and their extracellular vesicles can significantly reduce the serum levels of inflammatory markers in COVID-19 patients, with no serious adverse events. Trial registration IRCT, IRCT registration number: IRCT20200217046526N2. Registered 13th April 2020, http://www.irct.ir/trial/47073 .PMID:37365605 | DOI:10.1186/s13287-023-03402-8
Source: Cell Research - June 26, 2023 Category: Cytology Authors: Morteza Zarrabi Mohammad Amin Shahrbaf Masoumeh Nouri Faezeh Shekari Seyedeh-Esmat Hosseini Seyed-Mohammad Reza Hashemian Rasoul Aliannejad Hamidreza Jamaati Naghmeh Khavandgar Hediyeh Alemi Hoda Madani Abdoreza Nazari Azadeh Amini Seyedeh Nafiseh Hassani Source Type: research
Systematic review and meta-analysis of cell therapy for COVID-19: global clinical trial landscape, published safety/efficacy outcomes, cell product manufacturing and clinical delivery
This study summarizes 195 clinical trials of advanced cell therapies targeting COVID-19 that were registered over the two years between January 2020 to December 2021. In addition, this work also analyzed the cell manufacturing and clinical delivery experience of 26 trials that published their outcomes by July 2022. Our demographic analysis found the highest number of cell therapy trials for COVID-19 was in United States, China, and Iran (N=53, 43, and 19, respectively), with the highest number per capita in Israel, Spain, Iran, Australia, and Sweden (N=0.641, 0.232, 0,223, 0.194, and 0.192 trials per million inhabitants). ...
Source: Frontiers in Immunology - June 21, 2023 Category: Allergy & Immunology Source Type: research
GSE212003 Parallel use of human stem cell lung and heart models provide insights for SARS-CoV-2 treatment
Contributors : Rajeev Rudraraju ; Matthew J Gartner ; Jessica Neil ; Beth Stout ; Joseph Chen ; Elise Needham ; Michael See ; Charley Mackenzie-Kludas ; Leo Lee ; Mingyang Wang ; Hayley Pointer ; Kathy Karavendzas ; Dad Abu-Bonsrah ; Damien Drew ; Abbas Salavaty ; Peter D Currie ; Wai-Hong Tham ; Sean Humphrey ; Mirana Ramialison ; David Elliott ; Enzo Porrello ; Jose Polo ; Kanta SubbaraoSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) primarily infects the respiratory tract, but pulmonary and cardiac complications occur in ...
Source: GEO: Gene Expression Omnibus - June 13, 2023 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Serious Stem Cell Donation Events and Recipient Adverse Reactions Related to Severe Acute Respiratory Syndrome Coronavirus 2: Review of Reports to the World Marrow Donor Association
The severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) pandemic was initially feared to have detrimental impacts on unrelated donor hematopoietic stem cell (HSC) transplantation (HSCT). For HSCT recipients, the chief concern was that travel restrictions and donor self-isolation might prevent timely delivery of HSCs to recipients who had r eceived myeloablative conditioning, with potentially life-threatening consequences. Another worry was that a SARS-CoV-2-positive HSC donor could transmit the infection to an HSCT recipient.
Source: Biology of Blood and Marrow Transplantation - June 1, 2023 Category: Hematology Authors: Rachel Pawson, Chloe Anthias, Meghann Cody, Mirjam Fechter, Diane Fournier, Elizabeth O'Flaherty, Danielli Oliviera, Eefke van Eerden, Thilo Mengling Tags: Report Source Type: research
Possible cancer-causing capacity of COVID-19: Is SARS-CoV-2 an oncogenic agent?
Biochimie. 2023 May 23:S0300-9084(23)00136-0. doi: 10.1016/j.biochi.2023.05.014. Online ahead of print.ABSTRACTSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has shown diverse life-threatening effects, most of which are considered short-term. In addition to its short-term effects, which has claimed many millions of lives since 2019, the long-term complications of this virus are still under investigation. Similar to many oncogenic viruses, it has been hypothesized that SARS-CoV-2 employs various strategies to cause cancer in different organs. These include leveraging the renin angiotensin system, altering tumo...
Source: Biochimie - May 25, 2023 Category: Biochemistry Authors: Kasra Jahankhani Fatemeh Ahangari Ian M Adcock Esmail Mortaz Source Type: research
